Partner Robert Freedman Spoke with The Recorder on Private Biotechs Investing in Public Companies

With slower M&A movement in biotech in early 2023 and a slow-down in venture funding, companies are increasingly considering strategic acquisitions, spinoffs and other transactions that refine their investment. Partner Robert Freedman spoke with The Recorder about public company activity in the biotech sector and noted the uptick in reverse mergers which are also keeping the legal industry busy. “Private companies are chasing a fair amount of public companies,” Freedman said. “Sometimes they find a match, sometimes they don’t. Sometimes public companies get 50 bids, and they have to sort through all of them to find the best fit.”

Learn more here.